Inhibikase Therapeutics, Inc. IKT
At closeNov 10, 2026, 4:01 PM EST
After hours · Nov 10, 4:01 PM ET
- YTD
- -24.39%
- 1 year
- -2.52%
- Market cap
- 216.28M
- Revenue (ttm)
- 79.57K
- EPS (ttm)
- -0.43
- Shares out
- 67.19M
- Forward P/E
- -11.84
- YTD return
- -24.39%
- 1-year return
- -2.52%
- Volume
- 483.65K
- Avg volume
- 563.37K
- Open
- 1.65
- Previous close
- 1.68
- Day's range
- 1.53 – 1.65
- 52-week range
- 1.41 – 2.52
- Beta
- 1.12
- Price target
- 7.00 (+351.6%)
- Earnings date
- Aug 14, 2024
Key statistics
- Enterprise value
- 10.03M
- PEG ratio
- 0.00
- Price / sales
- 2499.56
- Price / book
- 1.67
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -10.34M
- Total cash
- 7.94M
- Total debt
- 355.09K
- Return on equity
- -149.69%
- Short % of float
- 0.29%
- 50-day average
- 2.62
- 200-day average
- 1.84
Analyst view
- Target (low)
- 5.00
- Target (mean)
- 7.00
- Target (high)
- 8.00
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.38 | -0.65 | -0.27 | -71.05% |
| Aug 14, 2024 | Jun 1, 2024 | -0.58 | -0.66 | -0.08 | -13.79% |
| Aug 14, 2024 | Jun 1, 2024 | -0.58 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.79 | -0.73 | +0.06 | +7.59% |
| May 15, 2024 | Mar 1, 2024 | -0.79 | — | — | — |
| Mar 27, 2024 | Dec 1, 2023 | -0.78 | -0.63 | +0.15 | +19.23% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2024 | Jefferies | init | — | Buy |
| Oct 14, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 16, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| May 21, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 5, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- inhibikase.com
News
Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity 
Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026 
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors 
Chardan Capital Initiates Coverage On Inhibikase Therapeutics with Neutral Rating, Announces Price Target of $1.5 
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Critical Survey: Inhibikase Therapeutics (NASDAQ:IKT) and Otsuka (OTCMKTS:OTSKY) 
Financial Review: Inhibikase Therapeutics (NASDAQ:IKT) vs. Eli Lilly and Company (NYSE:LLY) 
Inhibikase Therapeutics Q2 EPS $(0.11), Inline 
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity 
ADAR1 Capital Management LLC Reduces Stock Position in Inhibikase Therapeutics, Inc. $IKT
Your note
Sign in to keep a note on IKT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BELLINI ROBERTO | Director | Purchase | Oct 20, 2024 | 0 |
| KUSH ARVIND | Director | Purchase | Oct 20, 2024 | 145,000 |
| MUNSHI AMIT D | Director | Purchase | Oct 20, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 0.93% | 626,500 | 1.85M | Sep 29, 2024 |
| Blair (William) & Company, L.L.C. | 0.19% | 126,120 | 373.31K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.07% | 50,065 | 148.19K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.03% | 19,922 | 58.97K | Sep 29, 2024 |
| Vanguard Group Inc | 0.02% | 16,724 | 49.50K | Sep 29, 2024 |
| State Street Corporation | 0.02% | 10,084 | 29.85K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.05% | 36,382 | 107.69K | Oct 30, 2024 |
| 360 Funds-Timber Point Global Tactical Allocation Fd | 0.02% | 11,000 | 32.56K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.02% | 16,724 | 49.50K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.02% | 11,484 | 33.99K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.01% | 8,577 | 25.39K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.00% | 3,272 | 9.69K | Oct 30, 2024 |